AMGN — AMGEN INC catalysts
Next verified catalyst
2026-10-22 — A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) Wi · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-10-22 in 1mo
ESTIMATED |
READOUT
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndro
Phase 3 · Sjögren's Syndrome (SS) |
AMGN AMGEN INC | Dazodalibep |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|
| 2026-10-31 in 1mo
ESTIMATED |
READOUT
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC
Phase 2 · MTAP-deleted NSCLC |
AMGN AMGEN INC | anvumetostat |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|
| 2026-11-30 in 2mo
ESTIMATED |
READOUT
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MT
Phase 1/2 · Advanced MTAP-null Solid Tumors |
AMGN AMGEN INC | Anvumetostat, Docetaxel, Comparator Anvu |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|
| 2026-12-14 in 3mo
ESTIMATED |
READOUT
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
Phase 3 · Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) |
AMGN AMGEN INC | ABP 234, Pembrolizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|
| 2027-01-06 in 4mo
ESTIMATED |
READOUT
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Dis
Phase 1/2 · Thyroid Eye Disease |
AMGN AMGEN INC | AMG 732 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|
Past
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-09-11 9d ago
CONFIRMED |
APPROVED
IMDELLTRA
|
AMGN AMGEN INC | IMDELLTRA |
openFDA (drugsfda) ↗
✓ Source-checked 2026-09-20
Actual/recorded date
|